Annexon (ANNX) Operating Income (2019 - 2026)
Annexon's (ANNX) quarterly Operating Income came in at -$46.1 million in Q1 2026, up 19.78% year-on-year from -$38.4 million in Q1 2025, and up 8.37% quarter-over-quarter from -$50.3 million in Q4 2025.
Annexon (ANNX) Operating Income (2019 - 2026) Analysis & Trends
Annexon's Operating Income history runs 8 years deep, the most recent figure standing at -$46.1 million for Q1 2026.
- On a quarterly basis, Operating Income rose 19.78% year-over-year to -$46.1 million in Q1 2026; TTM through Mar 2026 was -$205.1 million, a 12.11% decrease from a year earlier, with the FY2025 full-year figure at -$216.4 million, down 40.46% from the prior year.
- Operating Income improved to -$46.1 million in Q1 2026 per ANNX's latest filing, from -$50.3 million in the prior quarter.
- Across five years, Operating Income topped out at -$28.6 million in Q1 2024 and bottomed at -$57.4 million in Q1 2025.
- The 5-year median for Operating Income is -$37.7 million (2023), against an average of -$41.5 million.
- Across the five-year window, Operating Income soared 30.72% in 2024 and plunged 100.91% in 2025, its largest moves.
- Year by year, Operating Income stood at -$36.7 million in 2022, then rose by 18.22% to -$30.0 million in 2023, then tumbled by 74.88% to -$52.5 million in 2024, then climbed by 4.23% to -$50.3 million in 2025, then grew by 8.37% to -$46.1 million in 2026.
- Per Business Quant, the three latest ANNX Operating Income figures stand at -$46.1 million (Q1 2026), -$50.3 million (Q4 2025), and -$57.0 million (Q3 2025).
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Op. Inc (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | -27.75 Mn |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | 249.90 Mn |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | -3.72 Mn |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | 1.14 Bn |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | 642.90 Mn |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | -32.68 Mn |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | 493.00 Mn |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | -445.22 Mn |
| 10 | Annexon | 1.03 Bn | 804.24 Mn | - | -46.05 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -46.05 Mn |
| Dec 31, 2025 | -50.26 Mn |
| Sep 30, 2025 | -57.02 Mn |
| Jun 30, 2025 | -51.73 Mn |
| Mar 31, 2025 | -57.41 Mn |
| Dec 31, 2024 | -52.48 Mn |
| Sep 30, 2024 | -39.44 Mn |
| Jun 30, 2024 | -33.58 Mn |
| Mar 31, 2024 | -28.57 Mn |
| Dec 31, 2023 | -30.01 Mn |
| Sep 30, 2023 | -34.78 Mn |
| Jun 30, 2023 | -37.69 Mn |
| Mar 31, 2023 | -41.24 Mn |
| Dec 31, 2022 | -36.70 Mn |
| Sep 30, 2022 | -36.07 Mn |
| Jun 30, 2022 | -37.41 Mn |
| Mar 31, 2022 | -35.43 Mn |
| Dec 31, 2021 | -37.46 Mn |
| Sep 30, 2021 | -35.68 Mn |
| Jun 30, 2021 | -31.37 Mn |